The phase III PHEDRA study has also demonstrated that the dual-targeted neoadjuvant regimen with pyrotinib and trastuzumab plus chemotherapy can provide clinical benefits in patients with HER2-positive breast cancer [19]. Here, ERBB2 is linked to breast cancer.